To further investigate the immunological mechanisms involved, we analyzed the expression of costimulatory molecules in aortic tissue and their counterpart molecules on infiltrating cells of patients with Takayasu’s arteritis. We also examined the expression of major histocompatibility complex (MHC) class I chain-related (MIC) A in aortic tissue, which is known to be induced by external stress, and its counterpart NKG2D receptors on infiltrating cells. Among these costimulatory molecules, strong expression of 4-1BBL and Fas was induced in the aortic tissue, and most of the infiltrating cells expressed 4-1BB and FasL, suggesting these pathways play critical roles in T-cell-mediated vascular injury. We also found that MICA was strongly induced in the aortic tissue and that at least part of the infiltrating cells expressed NKG2D receptors. Some infiltrating cells – but not vascular smooth muscle cells – seemed to have undergone apoptosis. Our findings strongly suggest that 4-1BB/4-1BBL and Fas/FasL pathways play important roles in vascular injury in Takayasu’s arteritis. We assume that γδ T cells infiltrated aortic tissue recognizing MICA, resulting in the induction of MHC antigens and costimulatory molecules, and then αβ T-cells infiltrated recognizing some auto-antigens presented by MHC antigens, leading to chronic inflammation.

Keywords:
4-1BBL, Costimulatory molecule, Fas, FasL, MICA, Takayasu’s arteritis, T cell
1.
Seko Y, Minota S, Kawasaki A, Shinkai Y, Maeda K, Yagita H, Okumura K, Sato O, Takagi A, Tada Y, Yazaki Y: Perforin-secreting killer cell infiltration and expression of a 65-kD heat-shock protein in aortic tissue of patients with Takayasu’s arteritis. J Clin Invest 1994;93:750–758.
2.
Seko Y, Sato O, Takagi A, Tada Y, Matsuo H, Yagita H, Okumura K, Yazaki Y: Restricted usage of T-cell receptor Vα-Vβ genes in infiltrating cells in aortic tissue of patients with Takayasu’s arteritis. Circulation 1996;93:1788–1790.
3.
Azuma M, Cayabyab M, Buck D, Phillips JH, Lanier LL: Involvement of CD28 in MHC-unrestricted cytotoxicity mediated by a human NK leukemia cell line. J Immunol 1992;149:1115–1123.
4.
Azuma M, Ito D, Yagita H, Okumura K, Phillips JH, Lanier LL, Somoza C: B70 antigen is a second ligand for CTLA-4 and CD28. Nature 1993;366:76–79.
5.
Maggi E, Annunziato F, Manetti R, Biagiotti R, Giudizi MG, Ravina A, Almerigogna F, Boiani N, Alderson M, Romagnani S: Activation of HIV expression by CD30 triggering in CD4+ T cells from HIV-infected individuals. Immunity 1995;3:251–255.
6.
Tozawa H, Andoh S, Takayama Y, Tanaka Y, Lee B, Nakamura H, Hayami M, Hinuma Y: Species-dependent antigenicity of the 34-kDa glycoprotein found on the membrane of various primate lymphocytes transformed by human T-cell leukemia virus type-I (HTLV-I) and simian T-cell leukemia virus (STLV-I). Int J Cancer 1988;41:231–238.
7.
Kayagaki N, Kawasaki A, Ebata T, Ohmoto H, Ikeda S, Inoue S, Yoshino K, Okumura K, Yagita H: Metalloproteinase-mediated release of human Fas ligand. J Exp Med 1995;182:1777–1783.
8.
Gavrieli Y, Sherman Y, Ben-Sasson SA: Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992;119:493–501.
9.
Seko Y, Takahashi N, Tada Y, Yagita H, Okumura K, Nagai R: Restricted usage of T-cell receptor Vγ-Vδ genes and expression of costimulatory molecules in Takayasu’s arteritis. Int J Cardiol 2000;75:S77–S83.
10.
Zweirner NW, Fernandez-Vina MA, Stastny P: MICA, a new polymorphic HLA-related antigen, is expressed mainly by keratinocytes, endothelial cells, and monocytes. Immunogenetics 1998;47:139–148.
11.
Bahram S, Bresnahan M, Geraghty DE, Spies T: A second lineage of mammalian major histocompatibility complex class I genes. Proc Natl Acad Sci USA 1994;91:6259–6263.
12.
Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, Spies T: Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999;285:727–729.
13.
Groh V, Steinle A, Bauer S, Spies T: Recognition of stress-induced MHC molecules by intestinal epithelial γδ T-cells. Science 1998;279:1737–1740.
14.
Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T: Broad tumor-associated expression and recognition by tumor-derived γδ T cells of MICA and MICB. Proc Natl Acad Sci USA 1999;96:6879–6884.
15.
Girardi M, Oppenheim DE, Steele CR, Lewis JM, Glusac E, Filler R, Hobby P, Sutton B, Tigelaar RE, Hayday AC: Regulation of cutaneous malignancy by γδ T cells. Science 2001;294:605–609.
16.
Nick S, Pileri P, Tongianti S, Uematsu Y, Kappos L, De Libero G: T-cell receptor γδ repertoire is skewed in cerebrospinal fluid of multiple sclerosis patient: Molecular and functional analysis of antigen-reactive γδ clones. Eur J Immunol 1995;25:355–363.
17.
Olive C, Gatenby PA, Serjeantson SW: Variable gene usage of T cell receptor γ- and δ-chain transcripts expressed in synovia and peripheral blood of patients with rheumatoid arthritis. Clin Exp Immunol 1992;87:171–177.
18.
De Libero G, Rocci MP, Casorati G, Giachino C, Oderda G, Tavassoli K, Migone N: T cell receptor heterogeneity in γδ T cell clones from intestinal biopsies of patients with celiac disease. Eur J Immunol 1993;23:499–504.
19.
Davis MM, Chien Y: Issues concerning the nature of antigen recognition by αβ and γδ T-cell receptors. Immunol Today 1995;16:316–318.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.